In a recent legal development, Sema4 Holdings Corp., a health diagnostics testing firm now operating as GeneDx Holdings Corp., is at the center of a revived securities class action. The case, reopened by a federal judge, alleges that the company’s presentation of its AI-driven clinical and genomic data platform, Centrellis, was significantly misleading. According to the court, statements made about Centrellis suggested its existence and capabilities were overstated, with testimony indicating the platform “did not exist or lacked the ability to utilize the data in accordance with its objectives.”
The original dismissal of the case, which took place in 2022, regarded the company’s claims as mere “puffery” or forward-looking statements. However, the court’s latest decision draws support from testimonies by former employees who asserted that Centrellis fell short of its advertised capabilities. The suit accuses Sema4 of contravening both the Securities Exchange Act of 1934 and SEC Rule 10b-5.
The ramifications of the legal scrutiny were felt by Sema4 as the market responded negatively to revelations about Centrellis, prompting a considerable drop in its stock value alongside significant organizational changes. The judgment suggests that the company’s executives might have been aware of the discrepancies between their public statements and the platform’s actual functionality. For more detailed insights, the original report on Law.com elaborates on the case proceedings and findings.